Advanced development of Lancet, an emerging tool for complex variant calling in cancer genomics

柳叶刀的高级开发，一种用于癌症基因组学中复杂变异调用的新兴工具

• 批准号: 10491232
• 负责人: Giuseppe Narzisi
• 金额: $ 49.08万
• 依托单位: NEW YORK GENOME CENTER
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-09-20 至 2024-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10491232
• 关键词: Address; Adoption; Advanced Development; Algorithms; Bandage; Behavior; Blood; Chromosomes; Color; Communities; Complex; Computer software; DNA sequencing; Data; Detection; Development; Disease; Disseminated Malignant Neoplasm; Documentation; Engineering; Event; Evolution; Genome; Genomic Segment; Goals; Graph; Haplotypes; Joints; Knowledge; Libraries; Link; Longitudinal cohort; Malignant Neoplasms; Manuals; Methods; Modeling; Modernization; Mutation; Patients; Performance; Phase; Play; Primary Neoplasm; Publications; Relapse; Research; Research Personnel; Resolution; Role; Sample Size; Sampling; Single Nucleotide Polymorphism; Somatic Mutation; Source Code; Structure; Testing; The Cancer Genome Atlas; Time; Update; Variant; Visualization; anticancer research; base; cancer cell; cancer genomics; cancer therapy; cohort; cost; data visualization; design; exome sequencing; genome analysis; genome sequencing; genome-wide; high throughput analysis; improved; improved functioning; insertion/deletion mutation; light weight; longitudinal analysis; novel strategies; performance tests; programs; prototype; tool; tumor; tumor progression; tumorigenesis; user-friendly; variant detection; web site; whole genome

ABSTRACT One of the central challenges in cancer genomics is the ability to accurately detect somatic mutations in heterogeneous tumors, and precisely determine their clonal origin and evolution. This fundamental knowledge is central to the discovery of new cancer therapies. In recent years, reductions in the cost of whole-genome and whole-exome sequencing have enabled researchers to address these questions in unprecedented detail. However, a major limitation in the field has been a paucity of methods for variant calling that extend beyond identifying simple single-nucleotide variants (SNVs) and small indels to allow the characterization of complex structural changes that also play a significant role in tumorigenesis and cancer progression. Indels of more than a few bases are challenging to discover with typically used alignment-based methods. In addition, most variant callers analyze tumor and normal data separately, which can introduce false positives such as when a mutation shows partial support in the normal sample. Towards addressing these shortcomings, we recently introduced Lancet, a new somatic variant caller developed under the auspices of the ITCR R21. Lancet leverages local assembly and joint analysis of tumor-normal paired data using region-focused colored de Bruijn graphs, with on- the-fly repeat composition analysis and a self-tuning k-mer strategy. This results in relatively reduced reference bias; an improved ability to detect variations that significantly diverge from the reference chromosome representations; a reduction in the scale of the analysis, leading to increased power and sensitivity to detect variants through localized, comprehensive graph exploration; and dynamic adjustment of calling behavior according to the sequence conditions of each genomic region. In testing, Lancet shows superior performance to all major alignment-based methods in terms of accuracy, particularly in the detection of ‘twilight zone’ indels (30- 250 bp). Given its continued adoption and successful application in over a dozen high-impact publications, Lancet is poised for more advanced development to enable continued improvements in its variant calling power, precision, and analytical capabilities. Specifically, Lancet is currently limited by longer runtimes than alignment- based methods, reduced sensitivity for longer insertions, lack of interactive visualization of the colored de Bruijn graph, and the inability to jointly analyze longitudinal data. To address these limitations, we propose the following Specific Aims: 1) Increase computational performance and facilitate user adoption and third-party development; 2) Add new features and enhancements to improve variant detection, phasing, and data visualization; and 3) Enable joint assembly and analysis of longitudinal data. Impact: With additional development, the next iteration of Lancet will feature advanced algorithms for fast, efficient, accurate, localized, user-friendly, and application- modifiable variant analysis of phased genome-wide timeseries data, establishing it as one of the leading methods for variant calling in cancer research.

摘要